title: Interleukin-10 and interleukin-6 in aqueous humor during treatment of vitreoretinal lymphoma with intravitreally injected methotrexate.
abstract: OBJECTIVE
  To evaluate the effectiveness of measuring anterior chamber interleukin (IL)-10 and IL-6 concentrations during treatment of vitreoretinal lymphoma with intravitreally injected methotrexate.
  
  
  METHODS
  Two patients (3 eyes) underwent repeated weekly intravitreal injections of methotrexate (400 microg of methotrexate/50 microl) for 6 weeks. We monitored the IL-10 and IL-6 concentrations in the anterior chamber and the IL-10/IL-6 ratio at baseline and at the last injections using a standard enzyme-linked immunoassay.
  
  
  RESULTS
  Repeated intravitreal injections of methotrexate reduced the vitreous opacity. The IL-10/IL-6 ratio decreased consistently in conjunction with clearance of the vitreous opacity in all 3 eyes, from 39.2 to 0.02, 1.67 to 0.03 and 3.05 to 0.159, respectively.
  
  
  CONCLUSIONS
  A decrease in the IL-10/IL-6 ratio seems to be related to a decrease in vitreous opacity. Measuring the IL-10/IL-6 ratio in the anterior chamber may be useful to evaluate the effect of treatment of vitreoretinal lymphoma.
authors: Department of Ophthalmology, Shiga University of Medical Science, Seta-tsukinowacho, Otsu, Japan. kawamura@belle.shiga-med.ac.jp
authors: Hajime
authors: H
authors: Kawamura
authors: Noriko
authors: N
authors: Yasuda
authors: Masashi
authors: M
authors: Kakinoki
authors: Tomoko
authors: T
authors: Sawada
authors: Osamu
authors: O
authors: Sawada
authors: Masahito
authors: M
authors: Ohji
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007267:Injections; D016753:Interleukin-10 / Q000032:analysis / Q000096:biosynthesis*; D015850:Interleukin-6 / Q000032:analysis / Q000096:biosynthesis*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D012160:Retina / Q000503:physiopathology; D016896:Treatment Outcome; D014822:Vitreous Body / Q000503:physiopathology
chemical_list: D000964:Antimetabolites, Antineoplastic; D015850:Interleukin-6; D016753:Interleukin-10; D008727:Methotrexate